Access all of the content
touchINFECTIOUSDISEASES were pleased to meet with Timothy Hinks (Nuffield Department of Medicine, University of Oxford, Oxford, UK) to discuss the results of the ATOMIC2 study results, investigating azithromycin in the treatment of COVID-19.
The abstract entitled: ‘A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19: the ATOMIC2 trial’ was presented at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), and the full paper is to be published in The Lancet Respiratory Medicine.
- What has the existing evidence taught us about the effectiveness of azithromycin in treating COVID-19? (0:09)
- What were the unique features of the ATOMIC2 study compared to existing studies? (1:32)
- What were the efficacy and safety findings in the study? (2:46)
- Why do you think that the addition of azithromycin to standard care failed to reduce hospitalisation, respiratory failure, or death in COVID-19 patients? (3:40)
- Is there a future role of azithromycin in the therapeutic paradigm for COVID-19? (4:37)
Disclosures: Timothy Hinks has received grants from Pfizer Inc., grants from University of Oxford, grants from the Wellcome Trust, grants from The Guardians of the Beit Fellowship, and grants from the NIHR Oxford Biomedical Research Centre during the conduct of the study; and personal fees from Astra Zeneca, personal fees from TEVA, personal fees from Peer Voice outside the submitted work.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed in coverage of the 31st ECCMID Congress 2021.
Share this Video
Related Videos In COVID-19
Paul Heath: Novavax Phase 3 Program of Clinical trials evaluating NVX-CoV2373 across the US, South Africa and UK [Part 2]
It was a great pleasure to meet with Prof. Paul Heath (St George’s, University of London, London, UK) to discuss the findings from the Novavax program of clinical trials evaluating the safety and efficacy of NVX-CoV2373 across the US, South Africa and the UK. Please find Part 1 of this interview available here. To access […]
Paul Heath: Phase 3 trial of Novavax Investigational COVID-19 vaccine [Part 1]
It was a great pleasure to meet with Prof. Paul Heath (St George’s, University of London, London, UK) to discuss the findings from the Phase III Novavax clinical trial that is investigating the safety and efficacy of NVX-CoV2373, a vaccine candidate for COVID-19. Please find Part 2 of this interview available here. To access more […]
Jeffrey Strich: Phase 2 Trial Results Investigating Fostamatinib for the treatment of COVID-19
It was a great pleasure to meet with Jeffrey Strich (National Institutes of Health Clinical Center, Bethesda, MD, USA) to discuss the findings from a recent phase 2 study investigating fostamatinib for the treatment of hospitalized adults with COVID-19. Useful Resources: Published data available here: Fostamatinib for the treatment of hospitalized adults with COVID-19 A […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!